Immunochromatography Device Detecting Z-AAT Protein
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for an effective lateral flow assay to determine the presence of the Z-AAT protein, which is under-diagnosed and often misdiagnosed as chronic obstructive pulmonary disease (COPD) or asthma, highlighting a gap in current diagnostic tools for Alpha-1 Antitrypsin Deficiency (AATD).
Innovation Solution
An immunochromatographic device with a membrane having a capture antibody bound to a test zone, specifically designed to detect Z-AAT protein using a sample application area, a microporous membrane with a Z-AAT protein capture area, and a conjugate structure with a gold-conjugated detection reagent, allowing for the determination of Z-AAT protein presence or amount in a fluid sample.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional lateral flow assays are used for AATD diagnosis, then the assay can detect common respiratory conditions, but the assay cannot accurately detect Z-AAT protein leading to under-diagnosis and misdiagnosis
Solution Approach 1:
The patent applies local quality by using specific capture antibodies (anti-Z-AAT antibodies) immobilized at the test zone of the membrane, rather than using general-purpose reagents throughout the entire device. This localized specialization enables selective and accurate detection of Z-AAT protein, directly resolving the inability of conventional assays to detect this specific analyte with sufficient precision.
Solution Approach 2:
The patent changes the biochemical parameters of the assay by introducing specific antibody-antigen interactions tailored for Z-AAT detection. The use of gold-conjugated detection reagents and specific capture antibodies modifies the binding characteristics and signal generation parameters, enabling reliable detection of Z-AAT protein that was previously undetectable or poorly detected by conventional methods.
2Measurement precision
If genetic testing is used for AATD diagnosis, then accurate identification of PiZ gene carriers can be achieved, but the process is complex, time-consuming, and only identifies 10-15% of cases
Solution Approach 1:
The patent replaces the complex molecular biology procedures of genetic testing with a simpler immunochromatographic assay based on antibody-antigen binding. This substitution maintains high identification accuracy for PiZ gene carriers while dramatically simplifying the diagnostic procedure, making it suitable for point-of-care use and enabling identification of the majority of cases rather than just 10-15%.
Solution Approach 2:
The immunochromatographic device is designed as a self-contained system that performs detection without requiring complex laboratory infrastructure, specialized equipment, or extensive operator training. The assay automatically processes the sample through capillary flow, with results visible through simple visual interpretation or basic optical reading, thereby reducing procedural complexity while maintaining diagnostic accuracy.
3Adaptability or versatility
If conventional diagnostic methods are used, then general respiratory conditions can be diagnosed, but Z-AAT protein detection is insufficient leading to misdiagnosis as COPD or asthma
Solution Approach 1:
The patent segments the diagnostic capability by incorporating a specific test zone on the membrane that is dedicated to Z-AAT detection, separate from other potential test zones. This segmentation allows the device to specifically target and detect Z-AAT protein while maintaining the ability to perform other diagnostics if needed, thereby preventing loss of diagnostic information about AATD that would occur with general-purpose methods.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The device enables accurate detection of Z-AAT protein in biological samples, facilitating the diagnosis of Alpha-1 Antitrypsin Deficiency and identifying PiZ gene carriers, thereby improving diagnostic accuracy and patient identification.
Implementation Method 1
The capture antibody is capable of binding with an analyte... formation of a complex between the capture antibody and the Z-AAT protein
Implementation Method 2
the detection reagent is gold-conjugated LG96 or a gold-conjugated antigen-binding fragment thereof
Implementation Method 3
a microporous membrane having a Z-AAT protein capture area... a flow path from the sample application area to the Z-AAT protein capture area
Data Source
AI summary
A membrane-based assay device, methods and kits for determining the presence or quantity of an analyte in a test sample are provided. The immunochromatographic device comprises a membrane having a capture antibody bound thereto at a test zone, wherein the capture antibody is capable of binding with an analyte, in particular a Z-AAT protein present in a sample from a PiZ gene carrier.